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The need for treatment is growing: Despite a decline in new HIV infections in some countries supported by the President’s 
Emergency Plan for AIDS Relief (PEPFAR), the total number of people living with HIV and requiring treatment continues to grow 
each year. If PEPFAR is at funded in 2016, it will not be able to meet the growing demand for treatment, jeopardizing progress in 
curbing the global epidemic. Investments in PEPFAR must increase to expand access to treatment, which, in addition to saving 
lives, is highly effective at preventing new infections.
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Investing in PEPFAR Expands Treatment,
Prevents Infection, Saves Lives
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Number of people on ARV treatment supported by PEPFAR
Number of new infections averted through treatment
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1. Estimates are based on annual increases to total PEPFAR budget and do not include increased funding for multilateral sources including the Global Fund.
2. Estimates are based on number of HIV infections prevented due to scale-up of ARV treatment among PLHIV and do not include additional benets of
 PEPFAR HIV prevention programming.
Increasing efficiencies: PEPFAR is 
among the most successful global health 
programs in history and is currently 
supporting 7.7 million people on lifesaving 
HIV treatment. Widespread use of generic 
drugs, coupled with improvements across 
ARV treatment and delivery systems, has 
helped dramatically reduce average annual 
per-patient treatment costs, from about 
$1,053 in 2005 to $315 in 2015. This has 
facilitated substantial increases in the 
number of people PEPFAR can support on 
ARV treatment, and has prevented millions 
of new HIV infections. 
